Arun C. Gulani, MD, introduces a keratoconus classification based on what prevents vision: visual, structural, or salvage.
Glaukos Corporation (NYSE: GKOS) announced results from a long-term Phase 3 extension study evaluating its Epioxa corneal cross-linking therapy for keratoconus, showing sustained efficacy and safety ...
Please provide your email address to receive an email when new articles are posted on . Optometrists are often first to diagnose a patient with keratoconus and hold a great responsibility for ...
Glaukos Corporation announced positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's ...
As most people are aware, there are two billing components for a corneal cross-linking treatment: the procedure, or T code, ...
LAGUNA HILLS, CA, UNITED STATES, July 10, 2026 /EINPresswire.com/ — Harvard Eye Associates is proud to announce the availability of Epioxa HD / Epioxa (“Epioxa ...
SEATTLE — Keeping our vision strong is important throughout life. Conditions like keratoconus, though, can cause vision to decline. “The cornea is important to be clear,” said Dr. Luke Barker of ...
PESHAWAR: Pakistan Institute of Community Ophthalmology at Hayatabad Medical Complex has decided to start the latest corneal procedures to be able to use all sorts of tissues sent by a US-based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results